Phio Pharmaceuticals Corp. (PHIO) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.0x

Market Cap

$12.60M

MomentumView details →

1D Return

−2.25%

YTD Return

+3.33%

RSI (14)

47.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.0x

Market Cap

$12.60M

RSI (14)

47.4

MomentumView details →

1D Return

−2.25%

YTD Return

+3.33%

SummaryUpdated Jun 1, 2026

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company founded in 2011 and headquartered in Marlborough, Massachusetts. Originally incorporated as RXi Pharmaceuticals Corporation, the company rebranded to its current name in November 2018. Phio specializes in developing immuno-oncology therapeutics using its proprietary INTASYL platform, which focuses on enhancing the body's immune system to fight cancer through innovative gene regulation techniques.

Ask drillr about Phio Pharmaceuticals Corp. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−102.40%

ROA (TTM)

−90.19%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+100.00%

FCF YoY

−70.87%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−59.34%

EBITDA YoY

−82.21%

EarningsView details →

EPS (Actual)

−$0.36

EPS Surprise

0.00%

Beats (12Q)

6/12

Next Q EPS Est

−$0.36

Avg Surprise (4Q)

4.11%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

15.87x

Quick Ratio

15.87x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−12.90M

Op. CF (TTM)

−12.20M

Next earningsNov 12, 2026 →

Latest newsMore news →

Phio Pharmaceuticals Corp. appointed R. Todd Plott, M.D. as a member of its Board of Directors and the Governance Committee, effective July 20, 2026.46d ago

Phio Pharmaceuticals commenced first commercial-scale cGMP production of its lead candidate PH-762 drug substance at Nitto Denko Avecia.72d ago

Similar companies

Aspire Biopharma Holdings, Inc.ASBP PDS Biotechnology CorporationPDSB BioLineRx Ltd.BLRX SeaStar Medical Holding CorporationICU MetaVia Inc.MTVA Ainos, Inc.AIMD Find similar companies →

Latest newsMore news →

Phio Pharmaceuticals Corp. appointed R. Todd Plott, M.D. as a member of its Board of Directors and the Governance Committee, effective July 20, 2026.46d ago Phio Pharmaceuticals commenced first commercial-scale cGMP production of its lead candidate PH-762 drug substance at Nitto Denko Avecia.72d ago